Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wolf O Bechstein

Showing results (121-130 of 143) with videos related to

Pageof 15
Sort By:
Annals of Surgical Oncology|March 8, 2024
Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer: The Randomized Multicenter Phase II NEPAFOX TrialThorsten O Goetze, Alexander Reichart, Ulli S Bankstahl, et al.
HPB : the Official Journal of the International Hepato Pancreato Biliary Association|September 16, 2021
Sarcopenia predicts reduced liver growth and reduced resectability in patients undergoing portal vein embolization before liver resection - A DRAGON collaborative analysis of 306 patientsJan Heil, Franziska Heid, Wolf O Bechstein, et al.
Transplantation|March 23, 2017
Practical Recommendations for Long-term Management of Modifiable Risks in Kidney and Liver Transplant Recipients: A Guidance Report and Clinical Checklist by the Consensus on Managing Modifiable Risk in Transplantation (COMMIT) GroupJames M Neuberger, Wolf O Bechstein, Dirk R J Kuypers, et al.
International Journal of Cancer|March 8, 2023
Perioperative FLOT plus ramucirumab for resectable esophagogastric adenocarcinoma: A randomized phase II/III trial of the German AIO and Italian GOIMThorsten O Goetze, Ralf-Dieter Hofheinz, Timo Gaiser, et al.
JAMA Oncology|November 18, 2021
Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer: Long-term Results of the CAO/ARO/AIO-12 Randomized Clinical TrialEmmanouil Fokas, Anke Schlenska-Lange, Bülent Polat, et al.
Transplantation|January 27, 2017
Advancing Transplantation: New Questions, New Possibilities in Kidney and Liver TransplantationJonas Wadström, Bo-Göran Ericzon, Philip F Halloran, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2019
Randomized Phase II Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: CAO/ARO/AIO-12Emmanouil Fokas, Michael Allgäuer, Bülent Polat, et al.
Annals of Surgery|August 2, 2021
Neoadjuvant Therapy for Resectable Pancreatic Cancer: A New Standard of Care. Pooled Data From 3 Randomized Controlled TrialsDominique L Birrer, Henriette Golcher, Riccardo Casadei, et al.
Annals of Surgery|September 1, 2018
Toward a Consensus on Centralization in SurgeryRené Vonlanthen, Peter Lodge, Jeffrey S Barkun, et al.
Zeitschrift Fur Gastroenterologie|September 9, 2024
Thomas Berg, Niklas F Aehling, Tony Bruns, et al.
Pageof 15

Showing results (121-130 of 143) with videos related to

Sort By:
Pageof 15
Annals of Surgical Oncology|March 8, 2024
Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer: The Randomized Multicenter Phase II NEPAFOX TrialThorsten O Goetze, Alexander Reichart, Ulli S Bankstahl, et al.
HPB : the Official Journal of the International Hepato Pancreato Biliary Association|September 16, 2021
Sarcopenia predicts reduced liver growth and reduced resectability in patients undergoing portal vein embolization before liver resection - A DRAGON collaborative analysis of 306 patientsJan Heil, Franziska Heid, Wolf O Bechstein, et al.
Transplantation|March 23, 2017
Practical Recommendations for Long-term Management of Modifiable Risks in Kidney and Liver Transplant Recipients: A Guidance Report and Clinical Checklist by the Consensus on Managing Modifiable Risk in Transplantation (COMMIT) GroupJames M Neuberger, Wolf O Bechstein, Dirk R J Kuypers, et al.
International Journal of Cancer|March 8, 2023
Perioperative FLOT plus ramucirumab for resectable esophagogastric adenocarcinoma: A randomized phase II/III trial of the German AIO and Italian GOIMThorsten O Goetze, Ralf-Dieter Hofheinz, Timo Gaiser, et al.
JAMA Oncology|November 18, 2021
Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer: Long-term Results of the CAO/ARO/AIO-12 Randomized Clinical TrialEmmanouil Fokas, Anke Schlenska-Lange, Bülent Polat, et al.
Transplantation|January 27, 2017
Advancing Transplantation: New Questions, New Possibilities in Kidney and Liver TransplantationJonas Wadström, Bo-Göran Ericzon, Philip F Halloran, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2019
Randomized Phase II Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: CAO/ARO/AIO-12Emmanouil Fokas, Michael Allgäuer, Bülent Polat, et al.
Annals of Surgery|August 2, 2021
Neoadjuvant Therapy for Resectable Pancreatic Cancer: A New Standard of Care. Pooled Data From 3 Randomized Controlled TrialsDominique L Birrer, Henriette Golcher, Riccardo Casadei, et al.
Annals of Surgery|September 1, 2018
Toward a Consensus on Centralization in SurgeryRené Vonlanthen, Peter Lodge, Jeffrey S Barkun, et al.
Zeitschrift Fur Gastroenterologie|September 9, 2024
Thomas Berg, Niklas F Aehling, Tony Bruns, et al.
Pageof 15